I regard golf as an expensive way of playing marbles." - G.K. Chesterton
Being in London this week, I thought today, we would take an in-depth look at a local developmental firm in today's article.
Company Overview:
Myovant Sciences (MYOV) IPO'd in 2016 and is a United Kingdom-based healthcare company focused on becoming a key player in the space of women's health and prostate cancer. The company's lead product candidate is Relugolix, which is being developed to treat symptoms of uterine fibroids, symptoms of endometriosis, and advanced prostate cancer. The company's other